Can extra antibodies shield myeloma patients from infections during cutting-edge therapy?

NCT ID NCT07094048

Recruiting now Disease control Sponsor: CHU de Quebec-Universite Laval Source: ClinicalTrials.gov ↗

First seen Jan 04, 2026 · Last updated May 13, 2026 · Updated 17 times

Summary

This study looks at multiple myeloma patients who are receiving a newer kind of immunotherapy called a BCMA-directed T cell engager. These treatments can weaken the immune system and raise the risk of serious infections. The trial will compare two target levels of immunoglobulin (antibody) support to see if a lower level works just as well as a higher level at preventing severe infections over three months. About 80 adults who have had at least one prior treatment will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA, REFRACTORY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Centre Intégré de Cancérologie
RECRUITING

Québec, Quebec, Canada

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

MULTIPLE MYELOMA, REFRACTORY RELAPSED MULTIPLE MYELOMA